Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Bryce V. Johnson"'
Publikováno v:
PLoS ONE, Vol 11, Iss 1, p e0146697 (2016)
Hypertrophic cardiomyopathy (HCM) is a leading cause of sudden cardiac death that often goes undetected in the general population. HCM is also prevalent in patients with cardio-facio-cutaneous syndrome (CFCS), which is a genetic disorder characterize
Externí odkaz:
https://doaj.org/article/30a3f1c19404425d8de4937e94eefa51
Autor:
Christian A. Bermudez, Bryce V. Johnson, Sriram D. Rao, Pavan Atluri, J. Eduardo Rame, Salim E. Olia, Edo Y. Birati, Lee R. Goldberg, Michael A. Acker, Venessa Medina, Joyce Wald, Jeremy A. Mazurek
Publikováno v:
Journal of Cardiac Failure. 26:870-875
Background Impella (Abiomed Inc, Danvers, MA) is a temporary mechanical support device positioned across the aortic valve, and can be used to support patient before LVAD implantation. There are no data on the incidence of aortic insufficiency (AI) in
Autor:
Bryce V, Johnson, Edward R, Horton, Christopher, Domenico, Ashwin S, Nathan, Alexander C, Fanaroff, Michael A, Acker, Daniel M, Kolansky
Publikováno v:
The Journal of invasive cardiology. 33(12)
We aimed to characterize outcomes associated with cangrelor administration used in an antiplatelet bridging strategy in real-world clinical scenarios within a large academic medical system.Cangrelor has been used for antiplatelet bridging in perioper
Autor:
Pavan Atluri, Michael V. Genuardi, Joyce Wald, S. Rao, Edo Y. Birati, Kimberly Urgo, Neha Mukunda, Lee R. Goldberg, Bryce V. Johnson
Publikováno v:
Journal of the American College of Cardiology. 77:749
Autor:
Wendy Keung, Kevin D. Costa, Peter Backeris, Evan S. Bardot, Camie W.Y. Chan, Bryce V. Johnson, Patrick K. W. Chan, Ronald A. Li, Andy O.-T. Wong, Timothy J. Cashman
Tissue engineers and stem cell biologists have made exciting progress toward creating simplified models of human heart muscles or aligned monolayers to help bridge a longstanding gap between experimental animals and clinical trials. However, no exist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1c272d7e49721ef3c3154026097d751
https://europepmc.org/articles/PMC6561506/
https://europepmc.org/articles/PMC6561506/
Autor:
Joshua Mayourian, Roger J. Hajjar, Deepak Kaji, Eric A. Sobie, Delaine K. Ceholski, Joshua M. Hare, Susmita Sahoo, Timothy J. Cashman, Bryce V. Johnson, David H. Sachs, Kevin D. Costa
Rationale: Myocardial delivery of human mesenchymal stem cells (hMSCs) is an emerging therapy for treating the failing heart. However, the relative effects of hMSC-mediated heterocellular coupling (HC) and paracrine signaling (PS) on human cardiac co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e66cb118c7370bb260ee98a4e47d8c07
https://europepmc.org/articles/PMC5899516/
https://europepmc.org/articles/PMC5899516/
Autor:
Wendy Keung, Ronald A. Li, Evan S. Bardot, Timothy J. Cashman, Bryce V. Johnson, Camie W. Chan, Patrick K. W. Chan, Andy O.-T. Wong, Kevin D. Costa, Peter Backeris
Publikováno v:
Journal of Pharmacological and Toxicological Methods. 99:106595
Autor:
Joyce Wald, Edo Y. Birati, Jeremy A. Mazurek, Kristy L. Kurcik, Sriram D. Rao, Bryce V. Johnson, Monique S. Tanna, Pavan Atluri
Publikováno v:
Journal of Cardiac Failure. 25:S174
Introduction The development of aortic incompetence (AI) after left ventricular assist device (LVAD) implantation occurs in 25-30% of all LVAD patients and contributes to increased morbidity. While the underlying pathophysiology is still unclear, pre
Publikováno v:
PLoS ONE
PLoS ONE, Vol 11, Iss 1, p e0146697 (2016)
PLoS ONE, Vol 11, Iss 1, p e0146697 (2016)
Hypertrophic cardiomyopathy (HCM) is a leading cause of sudden cardiac death that often goes undetected in the general population. HCM is also prevalent in patients with cardio-facio-cutaneous syndrome (CFCS), which is a genetic disorder characterize
Autor:
David M. Sachs, Timothy J. Cashman, Kevin D. Costa, Bryce V. Johnson, Eric A. Sobie, Joshua Mayourian, Deepak Kaji
Publikováno v:
Biophysical Journal. 112:162a
Myocardial delivery of human mesenchymal stem cells (hMSCs) is an emerging therapy for treating the failing heart. Demonstrated benefits include reduced fibrosis and enhanced contractile function, with predominant mechanisms thought to involve paracr